Enlivex Ltd. (NASDAQ:ENLV)
| Market Cap | 16.51M-93.9% |
| Revenue (ttm) | 0 |
| Net Income | 1.24B+8329.2% |
| EPS | 73.40+3540.5% |
| Shares Out | 16.83M |
| PE Ratio | 0.01 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 278,488 |
| Open | 1.04 |
| Previous Close | 1.04 |
| Day's Range | 0.98 - 1.06 |
| 52-Week Range | 0.98 - 27.15 |
| Beta | 1.42 |
| Analysts | Buy |
| Price Target | 15.00(+1429.52%) |
| Earnings Date | Sep 11, 2026 |
About ENLV
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
$ENLV stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ENLV holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ENLV's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ENLV Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ENLV patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ENLV from public contracts
Source: USAspending.gov
ENLV Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ENLV’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.